US 12,270,813 B2
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
Ugur Sahin, Mainz (DE)
Assigned to BioNTech SE, Mainz (DE)
Appl. No. 16/620,459
Filed by BioNTech SE, Mainz (DE)
PCT Filed Jun. 1, 2018, PCT No. PCT/EP2018/064468
§ 371(c)(1), (2) Date Dec. 6, 2019,
PCT Pub. No. WO2018/224405, PCT Pub. Date Dec. 13, 2018.
Claims priority of application No. PCT/EP2017/064140 (WO), filed on Jun. 9, 2017.
Prior Publication US 2020/0209251 A1, Jul. 2, 2020
Int. Cl. G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC G01N 33/68 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001156 (2018.08); A61K 39/001188 (2018.08); A61K 2039/53 (2013.01); A61K 2039/876 (2018.08); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01); G01N 2800/52 (2013.01)] 26 Claims
 
1. A method of making a cancer vaccine, the method comprising steps of:
for at least one cancer-specific amino acid modification within a peptide or polypeptide expressed in a cancer cell, determining whether the same or different fragments of the peptide or polypeptide, each of which fragment(s) comprises the same cancer-specific amino acid modification, meet selection criteria in that the same or different fragments:
(I) are presented by MHC molecules of different classes, and/or
(II) when presented by MHC molecules, are reactive with T cells restricted to different MHC classes;
selecting the cancer-specific amino acid modification if the same or different fragments meet the selection criteria; and
producing a vaccine that comprises (a) the peptide or polypeptide comprising the selected cancer-specific amino acid modification or a fragment thereof that meets the selection criteria; or (b) a nucleic acid encoding the peptide, polypeptide, or fragment of (a).